Friday, Aug 5, 1994

Genentech Opposes Recommendations to Make Growth Hormone a Scheduled Drug

Current controls in place minimize risk of abuse

South San Francisco, Calif. -- August 5, 1994 --

Genentech, Inc. (NYSE: GNE) opposes recommendations by the Foundation on Economic Trends to make growth hormone a controlled substance (Schedule III drug). There is insufficient evidence of growth hormone abuse to warrant it becoming a scheduled drug according to definitive government studies reported by respected medical groups. The Drug Enforcement Agency (DEA) has repeatedly rejected similar petitions in the past.

Genentech has voluntarily imposed controls on its distribution that eliminate the vast majority of abuse. Moreover, federal and state laws with very strict criminal penalties now exist that prohibit the distribution of growth hormone for non-medical uses such as athletic enhancement. Abuse potential is largely associated with muscle-building efforts in highly competitive athletic endeavors.

Scheduling could hamper the treatment of growth hormone inadequate children, making it more difficult for them to obtain the drug in adequate supplies and/or increasing the cost of obtaining the drug. Professional groups that represent those who treat growth hormone inadequate children such as the American Medical Association and the Lawson-Wilkins Pediatric Endocrine Society have previously expressed opposition to the scheduling of human growth hormone.

Genentech, Inc. is a leading biotechnology company that discovers, develops, manufactures and markets human pharmaceuticals for significant medical needs. The company has headquarters in South San Francisco, California and is traded on the New York and Pacific Stock exchanges under the symbol GNE.

# # #